
Organic Process Research and Development p. 1227 - 1238 (2016)
Update date:2022-08-03
Topics:
Williams, Michael J.
Chen, Qinghao
Codan, Lorenzo
Dermenjian, Renee K.
Dreher, Spencer
Gibson, Andrew W.
He, Xianliang
Jin, Yan
Keen, Stephen P.
Lee, Alfred Y.
Lieberman, David R.
Lin, Wei
Liu, Guiquan
McLaughlin, Mark
Reibarkh, Mikhail
Scott, Jeremy P.
Strickfuss, Sophie
Tan, Lushi
Varsolona, Richard J.
Wen, Feng
We describe the route development and multikilogram-scale synthesis of an HCV NS5B site D inhibitor, MK-8876. The key topics covered are (1) process improvement of the two main fragments; (2) optimization of the initially troublesome penultimate step, a key bis(boronic acid) (BBA)-based borylation; (3) process development of the final Suzuki-Miyaura coupling; and (4) control of the drug substance form. These efforts culminated in a 28 kg delivery of the desired active pharmaceutical ingredient.
View Morewebsite:http://www.hope-chem.com
Contact:86-21-58090396-805
Address:Floor 4, Building 5, No.588 Tianxiong Road, Zhoupu International Medical Zone, ShangHai, China
shijiazhuang baisheng chem co.; ltd
Contact:86-0311-80790826
Address:shijiazhuang hebei
Taizhou KEDE Chemical.Co.,Ltd.
Contact:86-576-84613060
Address:Jiangkou Chemical Zoon
Jinan Decheng Hemu Medical Technology Co.,Ltd.
Contact:+86-531-68650525
Address:NO.554 Zhengfeng Road High-new Technology Development Zone
JiangXi Keyuan Biopharma Co., LTD.
Contact:+86-563-6833666
Address:Guangde Fine Chemical Zone, Anhui Province, China
Doi:10.1016/0040-4039(94)02477-S
(1995)Doi:10.1038/nchem.2904
(2018)Doi:10.1021/jm050867d
(2006)Doi:10.1248/cpb.43.100
(1995)Doi:10.1021/op500222p
(2014)Doi:10.1016/j.bmcl.2014.07.019
(2014)